Early diagnosis of atherosclerosis and optimization of prevention of damage to the cardiovascular system in scleroderma in children
DOI:
https://doi.org/10.34687/2219-8202.JAD.2024.03.0001Keywords:
Scleroderma, atherosclerosis, dyslipidemia, cardiovascular eventsAbstract
Scleroderma is a very important medical and social problem. There is an increase in this disease among all age groups. The authors presented information on the results of a number of studies that indicate a change in the lipid profile of patients with scleroderma, which takes on an atherogenic character. In this regard, the main attention is paid to the mechanisms of the atherosclerotic process, contributing to the formation of various complications from the cardiovascular system in this pathology. An attempt has been made to describe in detail the pathogenesis of vascular disorders. Much attention is paid to the role of endothelial dysfunction, which has a very significant place in scleroderma. Attention is drawn to oxidative stress, which underlies vascular disorders, as an important pathogenetic link not only of atherosclerosis, but also of scleroderma, which unites these diseases. Endothelial dysfunction, detected both in scleroderma and other rheumatic diseases, can form already in the early stages of the disease and pose a threat to cardiovascular pathology, even such as myocardial infarction, acute cerebrovascular accident. The review provides information on the role of chronic inflammation in rheumatic diseases in the formation of atherosclerotic plaques. The connection between the pathogenesis of the main components of the metabolic syndrome and the formation of endothelial dysfunction, which causes the stimulation of fibrosis, is considered. An analysis of the presented information on atherogenic shifts in scleroderma allows us to conclude that doctors need to be wary of possible cardiovascular risks already in the early stages of the disease.
Downloads
References
Penin IN. Features of damage to the microcirculatory bed in systemic scleroderma: diss... c.m.s. St. Petersburg, 2021.
In Russian. (Пенин И.Н. Особенности поражения микроциркуляторного русла при системной склеродермии: дисс…
к.м.н. СПб, 2021).
Morbidity of the population by main classes, groups and individual diseases / CM Okladnikov, SYu Nikitina, GA
Alexandrova, RR Akhmetzyanova eds. In: Healthcare in Russia 2023: stat. coll. M.: Rosstat, 2023. P. 69-70. In Russian.
(Заболеваемость населения по основным классам, группам и отдельным болезням. / под ред. С.М. Окладнико-
ва, С.Ю. Никитиной, Г.А. Александровой, Р.Р. Ахметзяновой. В кн.: Здравоохранение в России 2023: стат. сб. М.:
Росстат, 2023. С. 32-33.)
The state of health of children aged 0-14 years / CM Okladnikov, SYu Nikitina, GA Alexandrova, RR Akhmetzyanova
eds. In: Healthcare in Russia 2023: stat. coll. M.: Rosstat, 2023. P. 69-70. In Russian. (Состояние здоровья детей в
возрасте 0-14 лет / под ред. С.М. Окладникова, С.Ю. Никитиной, Г.А. Александровой, Р.Р. Ахметзяновой. В кн.:
Здравоохранение в России 2023: стат. сб. М.: Росстат, 2023. С. 69-70).
Clunie G, Wilkinson N, Nikiphorou E, Jadon D. Systemic scleroderma and related diseases. In: Rheumatology. The
Oxford Handbook. AM Lila ed. M.: GEOTAR-Media, 2022. P. 610-611. In Russian. (Клуни Г., Уилкинсон Н., Никифо-
ру Е., Джейдон Д. Системная склеродермия и связанные заболевания. В кн.: редактор. Ревматология. Оксфорд-
ский справочник / под ред. А.М. Лилы. М.: ГЭОТАР-Медиа, 2022. С. 610-611).
Mazurov VI. Systemic scleroderma. In: Diffuse connective tissue diseases: a guide for doctors. M.: SIMK, 2011. 248 p.
In Russian. (Мазуров В.И. Системная склеродермия. В кн.: Диффузные болезни соединительной ткани: руковод-
ство для врачей. М.: Специальное издательство медицинских книг (СИМК), 2011. 248 с.).
Herrick AL. Raynaud's phenomenon. J Scleroderma Relat Dis. 2019;4(2):89-101. doi: 10.1177/2397198319826467.
Peralta-Amaro AL, Cruz-Domínguez MP, OlveraAcevedo A, Vera-Lastra OL. Prevalence of metabolic syndrome and
insulin resistance in system sclerosis. Rev Med Inst Mex Seguro Soc. 2015;53(4):476-483.
Aggoun Y, Bonnet D, Sidi D, Girardet JP, Brucker E, Polak M, et al. Arterial mechanical changes in children with
familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20(9):2070-2075. doi: 10.1161/01.atv.20.9.2070.
Leeson CP, Whincup PH, Cook DG, Mullen MJ, Donald AE, Seymour CA, Deanfield JE. Cholesterol and arterial
distensibility in the first decade of life: a population-based study. Circulation. 2000;101(13):1533-1538. doi: 10.1161/01.
cir.101.13.1533.
Tounian P, Aggoun Y, Dubern B, Lacorte JM, Clement K, Bonnet D, et al. Influence of polymorphisms in candidate genes
on early vascular alterations in obese children. Arch Cardiovasc Dis. 2010;103(1):10-18. doi: 10.1016/j.acvd.2009.10.001.
Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger Jr TA, Lucas M, Michet CJ, et al. Mortality in systemic
sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118(1):2-10. doi: 10.1016/j.
amjmed.2004.04.031.
Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, et al. The risk of cardiovascular disease in systemic sclerosis:
a population-based cohort study. Ann Rheum Dis. 2013;72(7):188-193. doi: 10.1136/annrheumdis-2012-202007.
Toth PP, Shaya GE, Leucker TM, Jones SR, Marthin SS. Coronary heart disease risk: Low-density lipoprotein and beyond.
Trends Cardiovasc Med. 2022;32(4):181-194. doi: 10.1016/j.tcm.2021.04.002.
Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J
Med. 2009;122(1 Suppl):S3-S14. doi: 10.1016/j.amjmed.2008.10.013.
Koskinas K, Chatzizisis Y, Baker A, Papafaklis MI, Coskun AU, Jarolim P, et al. Synergistic effect of local endothelial
shear stress and systemic hypercholesterolemia on coronary atherosclerotic plaque progression and composition in pigs.
Int J Cardiol. 2013;169(6):394-401. doi: 10.1016/j.ijcard.2013.10.021.
Muller-Ladner U, Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, et al. Predictors of progression in systemic
sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55(5):1902026. doi: 10.1183/13993003.02026-2019.
Gutiérrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernández-Avilés F. Endothelial dysfunction over the course
of coronary artery disease. Eur Heart J. 2013;34(41):3175-3181. doi: 10.1093/eurheartj/eht351.
Tartar DM, Chung L, Fiorentino D. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.
Clin Dermatol. 2018;36(4):508-524. doi: 10.1016/j.clindermatol.2018.04.008.
Ito T, Miura T, Mori T, Yamamoto T. Pediatric-onset solitary morphea profunda. Int J Dermatol. 2021;60(3):e116-e117.
doi: 10.1111/ijd.15078.
Asano Y, Fujimoto M, Ishikawa O, Sato S, Ihn H, Jinnin M, et al. Diagnostic criteria, severity classification and
guidelines of localized scleroderma. J Dermatol. 2018;45(7):755-780. doi: 10.1111/1346-8138.14161.
Moskalets OV. Cell adhesion molecules ICAM-1 and VCAM-1 in infectious pathology. RMJ. 2018;2:21-25. In Russian.
(Москалец О.В. Молекулы клеточной адгезии ICAM-1 и VCAM-1 при инфекционной патологии. РМЖ. 2018;2:21-25.
doi: 10.17238/PmJ1609-1175.2018.2.21–25).
Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Ann Rev Pathol. 2011;6:509-537. doi:
1146/annurev-pathol-011110-130312.
Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533. doi: 10.1038/s41586-021-03392-8.
Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173(1):35-43. doi: 10.1046/j.1365-
X.2001.00882.x.
Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol. 2009:27:165-197. doi:
1146/annurev.immunol.021908.132620.
Elshamy HA, Ibrahim SE, Farouk HM, Moustafa AA, Aly IM, Osman WM. N-terminal pro-brain natriuretic peptide in
systemic sclerosis: new insights. Eur J Dermatol. 2011;21(5):686-690. doi: 10.1684/ejd.2011.1423.
Antipova VN, Goncharova LN. Atherosclerosis and cardiovascular risk in rheumatic diseases. Ulyanovsk Medical and
Biological Journal. 2018;3;8-13. In Russian. (Антипова В.Н., Гончарова Л.Н. Атеросклероз и кардиоваскулярный
риск при ревматических заболеваниях. Ульяновский медико-биологический журнал. 2018;3;8-13. doi: 10.23648/
UMBJ.2018.31.17210).
George MJ, Kleveland O, Garcia-Hernandez J, Palmen J, Hingorani AD, Casas JP, et al. Novel Insights Into the Effects
of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics
Platform. J Am Heart Assoc. 2020;9(12):e015628. doi: 10.1161/JAHA.119.015628.
Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, et al. The association between inflammatory
markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis.
;73(7):1301-1308. doi: 10.1136/annrheumdis-2013-204715.
Udachkina HV, Novikova DS, Popkova TV, Kirillova IG, Markelova EI, Lukina GV, et al. Calcification of coronary
arteries in early rheumatoid arthritis prior to anti-rheumatic therapy. Rheumatol Int. 2018;38(2):211-217. doi: 10.1007/
s00296-017-3860-9.
Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann
N Y Acad Sci. 2001;947:93-111. doi: 10.1111/j.1749-6632.2001.tb03932.x.
Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, et al. Oxidative stress-mediated atherosclerosis: mechanisms and therapies.
Frontiers Physiol. 2017;23(8):600. doi: 10.3389/fphys.2017.00600.
Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species
in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular Pharmacology. 2018;100:1-19.
doi: 10.1016/j.vph.2017.05.005.
Varghese JF, Patel R, Yadav UCS. Novel insights in the metabolic syndrome-induced oxidative stress and inflammationmediated
atherosclerosis. Curr Cardiol Rev. 2018;14(1):4-14. doi: 10.2174/1573403X13666171009112250.
Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Sambo P, et al. Stimulatory autoantibodies to the PDGF
receptor in systemic sclerosis. N Engl J Med. 2006;22;354(25):2667-2676. doi: 10.1056/NEJMoa052955.
Shi-Wen X, Racanelli M, Ali A, Simon A, Quesnel K, Stratton RJ, Leask A. Verteporfin inhibits the persistent fibrotic
phenotype of lesional scleroderma dermal fibroblasts. J Cell Commun Signal. 2021;15(1):71-80. doi: 10.1007/s12079-
-00596-x.
Starovoitova MN, Desinova OV. Therapy of digital ulcers in patients with systemic scleroderma. Scientific and practical
rheumatology. 2018;56(6):777-781. In Russian. (Старовойтова М.Н., Десинова О.В. Терапия дигитальных язв у боль-
ных системной склеродермией. Научно-практическая ревматология. 2018;56(6):777-781. doi: 10.14412/1995-4484-
-777-781).
Herrick AL, Wigley FM. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2020;34(1):101474. doi: 10.1016/j.
berh.2019.101474.
Shevchenko AV, Prokofiev VF, Korolev MA, Omelchenko VO, Kononenkov VI. Polymorphism of genes of endothelial
dysfunction, coactivators of mitochondrial biogenesis and plasminogenplasmin system in the development of
cardiovascular complications in rheumatoid arthritis. Scientific and practical rheumatology. 2018;56(1):55-59. In
Russian. (Шевченко А.В., Прокофьев В.Ф., Королев М.А., Омельченко В.О., Кононенков В.И. Полиморфизм генов
эндотелиальной дисфункции, коактиваторов митохондриального биогенеза и плазминогенплазминовой системы
в развитии кардиоваскулярных осложнений при ревматоидном артрите. Научно-практическая ревматология.
; 6(1):55-59).
Yuan Q, Bai YP, Shi RZ, Liu SY, Chen XM, Chen L, et al. Regulation of endothelial progenitor cell differentiation
and function by dimethylarginine dimethylaminohydrolase 2 in an asymmetric dimethylarginine-independent manner.
Cell Biol Int. 2014;38(9):1013-1022. doi: 10.1002/cbin.10288.
Siervo M, Corander M, Stranges S, Bluck L. Post-challenge hyperglycaemia, nitric oxide production and endothelial
dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab Cardiovasc Dis. 2011;21(1):1-10. doi:
1016/j.numecd.2010.10.003.
Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, et al. Association of plasma
asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide
synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30(9):1142-1150.
doi: 10.1093/eurheartj/ehp061.
Surdacki A, Martens-Lobenhoffer J, Wloch A, Gluszko P, Rakowski T, Dubiel JS, et al. Plasma asymmetric dimethylarginine
is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism. 2009;58(3):316-
doi: 10.1016/j.metabol.2008.10.002.
Maslyansky AL, Zvartau NE, Kolesova EP, Kozlenok AV, Vasilyeva IM, Mazurov VI, et al. Subclinical Damage of the
Cardiovascular System in Patients with Rheumatological Diseases. Russian Journal of Cardiology. 2015;5(121):93-100.
In Russian. (Маслянский А.Л., Звартау Н.Э., Колесова Е.П., Козленок А.В., Васильева Е.Ю., Мазуров В.И. и др. Суб-
клиническое поражение сердечно-сосудистой системы у больных ревматологическими заболеваниями. Российский
кардиологический журнал. 2015;5(121):93-100. doi: 10.15829/1560-4071-2015-05-93-100).
Dessein PH, Solomon A, Hollan I. Metabolic abnormalities in patients with inflammatory rheumatic diseases. Best
Pract Res Clin Rheumatol. 2016;30(5):901-915. doi: 10.1016/j.berh.2016.10.001.
Arida A, Protogerou AD, Konstantonis G, Fragiadaki K, Kitas GD, Sfikakis PP. Atherosclerosis is not accelerated in
rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology
(Oxford). 2017;56(6):934-939. doi: 10.1093/rheumatology/kew506.
Boytsov SA, Kukharchuk VV, Karpov YuA, Sergienko IV, Drapkina OM, Semenova AE, Urazalina SZh. Subclinical
atherosclerosis as a risk factor for cardiovascular complications. Cardiovascular therapy and prevention. 2012;11(3):82-
In Russian. (Бойцов С.А., Кухарчук В.В., Карпов Ю.А., Сергиенко И.В., Драпкина О.М., Семенова А.Е., Уразали-
на С.Ж. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Кардиоваскулярная
терапия и профилактика. 2012;11(3):82-86. doi. 10.15829/1728-8800-2012-3-82-86).
Szekanecz Z, Besenyei T, Szentpetery A, Koch AE. VAngiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin
Rheumatol. 2010;22(3):299-306. doi: 10.1097/BOR.0b013e328337c95a.
Hettema ME, Bootsma H, Kallenbrg CGM. Macrovascular disease and atherosclerosis in systemic sclerosis. Rheumatology
(Oxford). 2008;47(5):578-583. doi: 10.1093/rheumatology/ken078.
Spanöli LG, Bonanno E, Sanjorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med. 2007;48(11):1800-
doi: 10.2967/jnumed.107.038661.
Shapiro MD, Fazio S. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Circ Res.
;118(4):732-749. doi: 10.1161/CIRCRESAHA.115.306471.
Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES, et al. High sensitivity C-reactive protein in systemic
lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus.
;14(8):576-582. doi: 10.1191/0961203305lu2157oa.
Poroshina LA. Optimization of treatment of focal scleroderma associated with metabolic syndrome. Health and
environmental issues. 2023;20(2):59-64. In Russian. (Порошина Л.А. Оптимизация лечения очаговой склеродер-
мии, ассоциированной с метаболическим синдромом. Проблемы здоровья и экологии. 2023;20(2):59-64). doi:
51523/2708- 6011.2023-20-2-08).
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation
by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-225. doi: 10.1177/1753944717711379.
Stefanadi EC, Dimitrakakis G, Antoniou CK, Challoumas D, Punjabi N, Punjabi S, et al. Metabolic syndrome and the
skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and
a clinical decision algorithm for high risk patients. Diabetol Metab Syndr. 2018;10:9. doi: 10.1186/s13098-018-0311-z.
Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Xiangyu P, Krueger JG, et al. Diverse activation and
differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J
Allergy Clin Immunol. 2016;137(1):118-129.e5. doi: 10.1016/j.jaci.2015.08.027.
Shilkina NP, Yunonin HER, Butusova SV, Mikhailova EV, Vinogradov AA. Endothelial Damage And Daily Blood Pressure
Profile In Rheumatoid Arthritis. Therapeutic Archive. 2019;81(5):89-95. In Russian. (Шилкина Н.П., Юнонин И.Е., Буту-
сова С.В., Михайлова Э.В., Виноградов А.А. Повреждение эндотелия и суточный профиль артериального давления
при ревматоидном артрите. Терапевтический архив. 2019;81(5):89-95). doi: 10.26442/00403660.2019.05.000052.
Novikova DS, Popkova TV, Gerasimov AN, Volkova AV, Nasonov EL. The relationship of cardiovascular risk factors
with arterial wall rigidity in women with high rheumatoid arthritis activity. Rational pharmacotherapy in cardiology.
;8(6):756-765. In Russian. (Новикова Д.С., Попкова Т.В., Герасимов А.Н., Волкова А.В., Насонов Е.Л. Взаимосвязь
кардиоваскулярных факторов риска с ригидностью артериальной стенки у женщин с высокой активностью
ревматоидного артрита. Рациональная фармакотерапия в кардиологии. 2012;8(6):756-765).
Ginzburg EB, Sosnova EA. Lipid peroxidation and the development of metabolic syndrome. Archive of Obstetrics and
Gynecology n.a. VF Snegirev. 2015;2(4):36-37. In Russian. (Гинзбург Е.Б., Соснова Е.А. Перекисное окисление липидов
и развитие метаболического синдрома. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2015;2(4):36-37).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ю. С. Богомолова, Г. В. Санталова
This work is licensed under a Creative Commons Attribution 4.0 International License.
